Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Laurie Menger,Erika Vacchelli,Sandy Adjemian,Isabelle Martins,Yuting Ma,Shensi Shen,Takahiro Yamazaki,Abdul Qader Sukkurwala,Mickael Michaud,Gregoire Mignot,Frederic Schlemmer,Eric Sulpice,Clara Locher,Xavier Gidrol,Francois Ghiringhelli,Nazanine Modjtahedi,Lorenzo Galluzzi,Fabrice Andre,Laurence Zitvogel,Oliver Kepp,Guido Kroemer
DOI: https://doi.org/10.1126/scitranslmed.3003807
IF: 17.1
2012-01-01
Science Translational Medicine
Abstract:Some successful chemotherapeutics, notably anthracyclines and oxaliplatin, induce a type of cell stress and death that is immunogenic, hence converting the patient's dying cancer cells into a vaccine that stimulates antitumor immune responses. By means of a fluorescence microscopy platform that allows for the automated detection of the biochemical hallmarks of such a peculiar cell death modality, we identified cardiac glycosides (CGs) as exceptionally efficient inducers of immunogenic cell death, an effect that was associated with the inhibition of the plasma membrane Na(+)- and K(+)-dependent adenosine triphosphatase (Na(+)/K(+)-ATPase). CGs exacerbated the antineoplastic effects of DNA-damaging agents in immunocompetent but not immunodeficient mice. Moreover, cancer cells succumbing to a combination of chemotherapy plus CGs could vaccinate syngeneic mice against a subsequent challenge with living cells of the same type. Finally, retrospective clinical analyses revealed that the administration of the CG digoxin during chemotherapy had a positive impact on overall survival in cohorts of breast, colorectal, head and neck, and hepatocellular carcinoma patients, especially when they were treated with agents other than anthracyclines and oxaliplatin.